ApTOLL对机械取栓后梗死体积与脑水肿的影响:APRIL试验二次分析
APRIL试验二次分析纳入136例急性大血管闭塞取栓患者,比较ApTOLL 0.2 mg/kg、0.05 mg/kg与安慰剂对72小时梗死体积、梗死增长及脑水肿的影响。ApTOLL 0.2 mg/kg独立关联最终梗死体积相对减少45.2%、梗死增长降低61.51%及水肿分级降低(共同OR 0.38),0.05 mg/kg无关联。
要点
- ApTOLL 0.2 mg/kg联合取栓使72小时最终梗死体积相对减少45.2%。
- ApTOLL 0.2 mg/kg使梗死增长降低61.51%,水肿分级共同OR为0.38。
- 0.05 mg/kg剂量未显示与梗死体积、增长或水肿的关联。
核心结论
- ApTOLL 0.2 mg/kg联合机械取栓显著降低72小时最终梗死体积、梗死增长及脑水肿。
- ApTOLL在易发生梗死增长的患者中可能更有效。
研究设计与样本
- APRIL试验的事后分析,2020至2022年在西班牙和法国进行。
- 纳入ApTOLL 0.05 mg/kg、0.2 mg/kg及安慰剂组患者,共136/139例有足够影像数据。
主要发现
- 与安慰剂相比,ApTOLL 0.2 mg/kg独立关联最终梗死体积相对减少-45.2%(95% CI -65%至-15%)。
- ApTOLL 0.2 mg/kg关联梗死增长降低61.51%(95% CI -79%至-29%)。
- ApTOLL 0.2 mg/kg关联水肿分级降低,共同OR 0.38(95% CI 0.15-0.96)。
- ApTOLL 0.05 mg/kg未发现与上述指标的关联。
- 交互分析显示入院核心体积较大、快速进展者及未完全再灌注患者中ApTOLL 0.2 mg/kg获益更大。
关键数值与推荐
- 早期梗死增长率定义为入院相对脑血流量<30%体积除以最后已知良好至成像时间,>10 mL/h为快速进展者。
- 脑水肿按SITS-MOST水肿量表评估:CED1较轻,CED2较重,CED3伴中线移位。
- 水肿分级分布:CED1 45%,CED2 34%,CED3 21%。
- 中位入院相对脑血流量<30%体积为18 mL,中位最终梗死体积为36.53 mL。
临床怎么用
- 对于前循环大血管闭塞取栓患者,ApTOLL 0.2 mg/kg可能减少最终梗死体积和脑水肿。
- 在核心体积较大、快速进展或再灌注不完全的患者中,ApTOLL 0.2 mg/kg可能获益更明显。
局限性
- 本研究为APRIL试验的事后分析。
- 样本量有限,共136例患者纳入影像分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: APRIL (A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke), a randomized placebo-controlled phase Ib/IIa trial, showed safety and reduced mortality and disability at 90 days of ApTOLL 0.2 mg/kg in combination with endovascular treatment in patients with acute large vessel occlusion within a 6-hour window. We studied the effect of ApTOLL against placebo on final infarct volume, infarct growth, and cerebral edema. METHODS: Post hoc analysis of a trial was conducted between 2020 and 2022 in Spain and France. Patients allocated to ApTOLL doses of 0.05 and 0.2 mg/kg and placebo were selected. The early infarct growth rate was defined as admission relative cerebral blood flow <30% volume/time elapsed from last-known well to imaging, considering fast progressors when >10 mL/h. An imaging core laboratory evaluated final infarct volume and cerebral edema on fluid-attenuated inversion recovery or noncontrast computed tomography at 72 hours if fluid-attenuated inversion recovery was not available. Cerebral edema was evaluated according to the SITS-MOST (Safe Implementation of Thrombolysis in Stroke-Monitoring Study) edema scale (cerebral edema degree [CED]; less severe: CED1; more severe: CED2; and with midline shift: CED3). Infarct growth was calculated as the final infarct volume: relative cerebral blood flow <30% volume at admission. Associations were studied through linear or ordinal models adjusted by prespecified variables. Admission relative cerebral blood flow <30% volume, fast recruitment, and final expanded Thrombolysis in Cerebral Infarction, among others, were examined for interaction with ApTOLL on final infarct volume and CED. RESULTS: A total of 136 of 139 patients had sufficient radiological data. Median admission relative cerebral blood flow <30% was 18 mL, and median final infarct volume was 36.53 mL. Edema grade was CED1 in 45%, CED2 in 34%, and CED3 in 21% patients. Compared with placebo, ApTOLL 0.2 mg/kg was independently associated with a lower final infarct volume (relative reduction, -45.2% [95% CI, -65% to -15%]), a lower infarct growth (61.51% [95% CI, -79% to -29%]), and a lower edema grade (common odds ratio, 0.38 [95% CI, 0.15-0.96]). No associations were found for ApTOLL 0.05 mg/kg. The study of interactions showed a greater benefit of ApTOLL 0.2 mg/kg among patients with larger core volume at admission, fast progressors, and patients achieving incomplete reperfusion (expanded Thrombolysis in Cerebral Infarction <2b). CONCLUSIONS: ApTOLL 0.2 mg/kg in combination with mechanical thrombectomy significantly reduced final infarct volume, infarct growth, and cerebral edema at 72 hours. ApTOLL seemed to be more effective under conditions prone to infarct growth.
引用
- Hernández-Pérez M, Valls-Carbó A, Hernández-Jiménez M, et al. Changes in Infarct Volume and Cerebral Edema After Mechanical Thrombectomy in Patients With Stroke Randomized to ApTOLL or Placebo: A Secondary Analysis of APRIL Trial. Stroke. 2025. PMID: 40677233. doi:10.1161/STROKEAHA.124.048917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。